Sintx Technologies, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 46 rows, 46 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-09-01: Reporting owner O'Brien David Francis; Form 3; Security Stock Option*; Transaction Holding.
- 2020-09-01: Reporting owner O'Brien David Francis; Form 3; Security Stock Option*; Transaction Holding.
- 2020-09-01: Reporting owner O'Brien David Francis; Form 3; Security Stock Option*; Transaction Holding.
- 2016-09-14: Reporting owner Bal Bhajanjit; Form 4; Security Stock Options; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
SINT insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-09-01 holding as of filing | O'Brien David Francis Officer (Chief Operating Officer) | 3 | Stock Option* Derivative · Direct | Holding | $5,130.00 exercise price | 2020-09-01 | ||
| 2020-09-01 holding as of filing | O'Brien David Francis Officer (Chief Operating Officer) | 3 | Stock Option* Derivative · Direct | Holding | $5,221.80 exercise price | 2020-09-01 | ||
| 2020-09-01 holding as of filing | O'Brien David Francis Officer (Chief Operating Officer) | 3 | Stock Option* Derivative · Direct | Holding | $608.04 exercise price | 2020-09-01 | ||
| 2016-09-14 | Bal Bhajanjit Director, Officer (CEO/President) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 19,318 owned after | $1.02 exercise price | $7,344,000.00 | 2016-09-16 |
| 2016-01-04 | White Jeffrey S. Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 70,000 owned after | $0.11 exercise price | $12,204,000.00 | 2016-01-06 |
| 2016-01-04 | Truetzel David W. Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 261,395 owned after | $0.11 exercise price | $12,204,000.00 | 2016-01-06 |
| 2016-01-04 | Stookey Eric A Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 70,000 owned after | $0.11 exercise price | $12,204,000.00 | 2016-01-06 |
| 2016-01-04 | McEntire Bryan J. Officer (Chief Technology Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 220,000 owned after | $0.11 exercise price | $12,204,000.00 | 2016-01-06 |
| 2016-01-04 | LOMBARDI TY Officer (CFO) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 149,000 owned after | $0.11 exercise price | $12,204,000.00 | 2016-01-06 |
| 2015-10-01 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 246,395 owned after | $0.31 exercise price | $33,912,000.00 | 2015-10-19 |
| 2015-09-16 | Bal Bhajanjit Director, Officer (CEO/President) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 140,119 owned after | $0.43 exercise price | $46,440,000.00 | 2015-09-18 |
| 2015-07-01 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 201,395 owned after | $0.60 exercise price | $64,800,000.00 | 2015-07-07 |
| 2015-01-20 holding as of filing | LOMBARDI TY Officer (VP Finance) | 3 | Stock Options Derivative · Direct | Holding | $0.95 exercise price | 2015-01-20 | ||
| 2015-01-20 holding as of filing | LOMBARDI TY Officer (VP Finance) | 3 | Stock Options Derivative · Direct | Holding | $0.97 exercise price | 2015-01-20 | ||
| 2015-01-08 | ONTIVEROS KEVIN Other (Former CLO and CCO) | 4 | Stock Options Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 0 owned after | $2.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | ONTIVEROS KEVIN Other (Former CLO and CCO) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Davis Kevin L Other (former Chief Operating Officer) | 4 | Stock Options Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 0 owned after | $2.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Davis Kevin L Other (former Chief Operating Officer) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Truetzel David W. Director | 4 | Stock Options Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −6,395 105,000 owned after | $2.47 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Truetzel David W. Director | 4 | Stock Options Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −45,000 60,000 owned after | $1.45 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,395 66,395 owned after | $0.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 111,395 owned after | $0.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | McEntire Bryan J. Officer (Chief Technology Officer) | 4 | Stock Options Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 70,000 owned after | $2.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | McEntire Bryan J. Officer (Chief Technology Officer) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 170,000 owned after | $0.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Whitfield Christopher Officer (Chief Commercial Officer) | 4 | Stock Option Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −100,000 70,000 owned after | $2.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-08 | Whitfield Christopher Officer (Chief Commercial Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 170,000 owned after | $0.95 exercise price | $102,600,000.00 | 2015-01-13 |
| 2015-01-07 | White Jeffrey S. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 55,000 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2015-01-07 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 96,395 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2015-01-07 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 111,395 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2015-01-07 | Stookey Eric A Director | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 55,000 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2015-01-07 | Whitfield Christopher Officer (Chief Commercial Officer) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +70,000 170,000 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2015-01-07 | McEntire Bryan J. Officer (Chief Technology Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +70,000 170,000 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2015-01-07 | Bal Bhajanjit Director, Officer (CEO/President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,500 90,313 owned after | $0.97 exercise price | $104,436,000.00 | 2015-01-09 |
| 2014-12-29 | White Jeffrey S. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $0.68 exercise price | $73,440,000.00 | 2014-12-31 |
| 2014-12-29 | Stookey Eric A Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $0.68 exercise price | $73,440,000.00 | 2014-12-31 |
| 2014-10-01 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 51,359 owned after | $1.45 exercise price | $156,600,000.00 | 2014-10-03 |
| 2014-09-18 | Truetzel David W. Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,395 6,395 owned after | $2.47 exercise price | $266,760,000.00 | 2014-10-03 |
| 2014-08-18 holding as of filing | ESPLIN GORDON Officer (Vice President, Finance) | 3 | Stock Options Derivative · Direct | Holding | no price filed | 2014-08-18 | ||
| 2014-08-13 | Olson Eric K. Director, Officer (President and CEO) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $2.95 exercise price | $318,600,000.00 | 2014-08-15 |
| 2014-08-13 | Whitfield Christopher Officer (Chief Commercial Officer) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $2.95 exercise price | $318,600,000.00 | 2014-08-15 |
| 2014-08-13 | ONTIVEROS KEVIN Officer (See Remarks) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $2.95 exercise price | $318,600,000.00 | 2014-08-15 |
| 2014-08-13 | McEntire Bryan J. Officer (Chief Technology Officer) | 4 | Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $2.95 exercise price | $318,600,000.00 | 2014-08-15 |
| 2014-08-13 | Davis Kevin L Officer (Chief Operating Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $2.95 exercise price | $318,600,000.00 | 2014-08-15 |
| 2014-02-12 holding as of filing | Bal Bhajanjit Director | 3 | Stock Options (right to buy) Derivative · Direct | Holding | no price filed | 2014-02-12 | ||
| 2014-02-12 holding as of filing | McEntire Bryan J. Officer (Chief Technology Officer) | 3 | Stock Options (right to buy) Derivative · Direct | Holding | no price filed | 2014-02-12 | ||
| 2014-02-12 holding as of filing | LINK MAX Director | 3 | Stock Options (right to buy) Derivative · Direct | Holding | no price filed | 2014-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | United States | $0.012B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B |